No Detail Found!

Role of 68Ga-PSMA PET/CT in Patients with Recurrent Prostate Cancer and its Comparison with Serum PSA Levels and Gleason Scores

Author(s)
Syed Rashid-ul- Amin Department of Nuclear Medicine and Molecular Imaging, Sindh Institute of Urology and Transplantation (SIUT), Karachi, Pakistan
Abdul Hai Department of Nuclear Medicine and Molecular Imaging, Sindh Institute of Urology and Transplantation (SIUT), Karachi, Pakistan
Haider Ali Department of Nuclear Medicine and Molecular Imaging, Sindh Institute of Urology and Transplantation (SIUT), Karachi, Pakistan
Najeeb Niamatullah Department of Oncology, Sindh Institute of Urology and Transplantation (SIUT), Karachi, Pakistan.
Altaf Hashmi Department of Urology, Sindh Institute of Urology and Transplantation (SIUT), Karachi, Pakistan
Abstract
Background: Biochemical recurrence is seen in 27-53% of carcinoma prostate patients after treatment. GS (Gleason score) and baseline PSA level are a predictor of recurrence. Post- treatment persistent rising PSA levels represent the recurrence and PSMA labelled PET-CT is an important part of imaging workup in these patients. Objective: To detect the relationship between PSA levels and Gleason score in patients investigated for Gallium-PSMA-11 fused molecular imaging in biochemical recurrent carcinoma prostate. Material and Methods: This cross-sectional study was carried out at S.I.U.T Karachi. PSMA-PET/CT scans (September 2017-January 2022) of the patient who had a biochemical recurrence and not receiving any cancer-specific treatment at least 4 weeks prior scan were included. PSA level from lab reports and GS from the histopathological reports was recorded. Biochemical recurrence were defined as when PSA level > 0.4 ng/ml (post-prostatectomy) or >2.0 ng/ml higher than the nadir value after radiotherapy. PET/CT scans of 106 included patients were interpreted by the nuclear physician and radiologist team. SUVmax = 2.5 was considered positive for recurrence. Local recurrences, lymph nodal, osseous, and visceral metastasis were documented. Statistical analysis was done by utilizing IBM SPSS software (version 22.0). Results: In 88 of 106 patients (83%), Gallium-PSMA-11 PET/CT scan detected at least one lesion characteristic of recurrent PCa. The median PSA level was 12.1 (.01-892.0) ng/dl. In relating PSA value, it was noted that there was a significant difference between lesion positive and negative PSMA-11 labelled Ga-68 PET/CT scan but not statically significant for GS. Local recurrences were seen in 70 patients, whereas lymph node and osseous metastases were noted in 64 and 52 scans respectively. A PSA value of 0.68 ng/ml was determined by utilizing the ROC curve with an AUC of 0.924 (95% CI 0.86-0.98) and will likely predict the positive/negative PSMA-11 Gallium PET/CT scan.Conclusion: Raised PSA level may predict the possibility of a positive Ga-PSMA-11 PET/CT scan but there was no relationship noted between GS and Ga-PSMA-11 PET/CT findings.
Publication Details
Page(s) 115-120
Published Journal: National Journal of Health Sciences, Volume: 7, Issue: 3, Year: 2022

Request the full text from PASTIC

Keywords
Metastases, Gleason score, PSMA-11 labelled Gallium PET/CT scan, Non-metastatic prostate cancer, Biochemical recurrent carcinoma prostate, PSA level
0

Citations

0

Downloads

59

Views